本報道最初發表于Endpoints News。請點擊這里查看原文
The government on Tuesday announced final prices for the second round of drugs negotiated by Medicare under the Inflation Reduction Act, including for Novo Nordisk’s blockbuster semaglutide products Ozempic and Wegovy.
政府于周二公布了依據《降低通脹法》(Inflation Reduction Act, IRA)由聯邦醫療保險計劃第二輪議價藥品的最終價格,其中包括諾和諾德(Novo Nordisk)的重磅司美格魯肽產品——諾和泰(Ozempic)和諾和盈(Wegovy)。
您已閱讀5%(378字),剩余95%(6585字)包含更多重要信息,訂閱以繼續探索完整內容,并享受更多專屬服務。